Eprosartan mesylate in controlling of blood pressure in patients with ischemic stroke
Martynov, M.Iu.; Boĭko, A.N.; Petukhov, E.B.; Berezov, V.P.; Maskarov, A.N.; Gusev, E.I.
Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 102(4): 26-30
2002
ISSN/ISBN: 1997-7298 PMID: 12001661 Document Number: 543228
In 20 patients with ischemic stroke and moderate or severe arterial hypertension the effectiveness of eprosartan mesilat (Teveten, Solway Farma, Germany) for a period of 6 months was studied. Patients received 600 mg of eprosartan mesilat daily and in 4 cases hydrochlortyaside was also added. Monotherapy with eprosartan mesilat was effective in all patients with moderate arterial hypertension and in 43,6% in patients with severe arterial hypertension. Therapy with eprosartan mesilat was associated with significant hypotensive effect (more evident in patients with high systolic blood pressure), improvement in 24-hour blood pressure profile and quality of life, and lower probability of secondary stroke. Side effects were not observed.